[Zanubrutinib (chronic lymphocytic leukaemia) – Addendum to Commission A22-130]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005106
Original Title: Zanubrutinib (nicht vorbehandelte chronische lymphatische Leukämie) - Addendum zum Projekt A22-130 (Dossierbewertung)
Project Status: Completed
Year Published: 2023
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Antineoplastic Agents
  • Hematologic Agents
  • Protein Kinase Inhibitors
  • Zanubrutinib
  • Leukemia – Lymphocytic – Chronic – B-Cell
  • Benefit Assessment
  • NCT03336333
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.